Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome

Mazetto, Bruna de Moraes; Hounkpe, Bidossessi Wilfried; Saraiva, Sabrina da Silva; Vieira-Damiani, Gislaine; Santos, Ana Paula Rosa dos; Jacinto, Bruna Cardoso; Vaz, Camila de Oliveira; Mesquita, Gabriela Tripiquia Vechiatto; Annichino‐Bizzacchi, Joyce Maria; Paula, Erich Vinícius De; Orsi, Fernanda Andrade

doi:10.1016/j.thromres.2022.05.001

Cited by 26 publications

(15 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Neutrophils are also involved in thrombus formation in patients with APS. Studies showed that plasma levels of cell-free DNA and NETs were higher in patients with primary APS than in healthy controls [ 34 , 35 , 36 ]. Similar results are reported in pregnant women with APS [ 37 ].…”

Section: Physiopathology Of Thrombosis In Apsmentioning

confidence: 99%

Anticoagulant Therapy in Patients with Antiphospholipid Syndrome

Capecchi

Abbattista

Ciavarella

et al. 2022

JCM

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the persistent positivity of antiphospholipid antibodies (aPLA) together with thrombosis or obstetrical complications. Despite their recognized predominant role, aPLA are not sufficient to induce the development of thrombosis and a second hit has been proposed to be necessary. The mainstay of treatment of APS is anticoagulant therapy. However, its optimal intensity in different presentations of the disease remains undefined. Moreover, decision on which patients with aPLA would benefit from an antithrombotic prophylaxis and its optimal intensity are challenging because of the lack of stratification tools for the risk of thrombosis. Finally, decision on the optimal type of anticoagulant drug is also complex because the central pathway responsible for the development of thrombosis is so far unknown and should be carried out on an individual basis after a careful evaluation of the clinical and laboratory features of the patient. This review addresses the epidemiology, physiopathology, diagnosis and management of thrombosis and obstetrical complications in APS, with a special focus on the role of direct oral anticoagulants.

show abstract

Section: Physiopathology Of Thrombosis In Apsmentioning

confidence: 99%

Anticoagulant Therapy in Patients with Antiphospholipid Syndrome

Capecchi

Abbattista

Ciavarella

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…A cross-sectional study found that NETs contribute to activated protein C resistance, which plays a role in the hypercoagulable condition of APS individuals ( Foret et al, 2022 ). Mazetto et al ( Mazetto et al, 2022 ) recently reported that patients with thrombotic APS have elevated levels of gene expression associated with neutrophil activity and the release of NETs, which may be involved in thrombus formation.…”

Section: Discussionmentioning

confidence: 99%

Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012–2021)

Huang²,

Qi³

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objectives: A growing body of studies related to antiphospholipid syndrome (APS) have been published in recent years. Nevertheless, there is a lack of visualized and systematic analysis in the literature on APS. Hence, this study sought to conduct a bibliometric analysis to identify research status and discover frontiers in the field.Methods: Articles and reviews concerning APS were acquired from the Web of Science Core Collection (WoSCC) database. CiteSpace, VOSviewer and a bibliometric online analysis platform were employed to conduct a visualization and knowledge-map analysis.Results: A total of 1,390 publications regarding APS were identified. Globally, Italy contributed the most publications. The University of Padua was the most productive institution. Lupus ranked first in both the most published and most co-cited journals. Savino Sciascia and Spiros Miyakis were the most prolific and most co-cited authors, respectively. “Vitamin K antagonists (VKA)” and “immunoglobulin A (IgA)” were current research foci. Burst analysis of keywords suggested that “neutrophil extracellular trap (NET),” “direct oral anticoagulant (DOAC),” “open label,” “outcome,” “hydroxychloroquine (HCQ),” and “arterial thrombosis (AT)” were significant future research frontiers.Conclusion: The scientific literature on APS has increased steadily in the past 10 years. The clinical studies on the treatment and mechanism research of APS are recognized as promising research hotspots in the domain of APS. The research status and trends of APS publications from the bibliometric perspective can provide a practical guide and important reference for subsequent studies by researchers and physicians in the domain.

show abstract

“…The pro-thrombotic action of NETs could be relevant for the pathogenesis of APS. An increase in the plasma concentration of NET by-products has in fact been documented in patients with vascular APS ( 41 ). The increase may reflect a higher NET generation, a lower NET degradation rate or both ( 42 ).…”

Section: Neutrophils Nets and Apsmentioning

confidence: 96%

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

Grossi

Capitani²,

Benagiano³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent vascular thrombosis and miscarriages in the absence of known causes. Antibodies against phospholipid-binding proteins (aPL) are pathogenic players in both clotting and pregnancy APS manifestations. There is sound evidence that antibodies specific for beta2 glycoprotein I (β2GPI) trigger thrombotic and pregnancy complications by interacting with the molecule on the membranes of different cell types of the coagulation cascade, and in placenta tissues. In addition to the humoral response against β2GPI, both peripheral and tissue CD4+ β2GPI-specific T cells have been reported in primary APS as well as in systemic lupus erythematosus (SLE)-associated APS. While adaptive immunity plays a clear role in APS, it is still debated whether innate immunity is involved as well. Acute systemic inflammation does not seem to be present in the syndrome, however, there is sound evidence that complement activation is crucial in animal models and can be found also in patients. Furthermore, neutrophil extracellular traps (NETs) have been documented in arterial and venous thrombi with different etiology, including clots in APS models. Keeping in mind that β2GPI is a pleiotropic glycoprotein, acting as scavenger molecule for infectious agents and apoptotic/damaged body constituents and that self-molecules externalized through NETs formation may become immunogenic autoantigens, we demonstrated β2GPI on NETs, and its ability to stimulate CD4+β2GPI-specific T cells. The aim of this review is to elucidate the role of β2GPI in the cross-talk between the innate and adaptive immunity in APS.

show abstract

Association between neutrophil extracellular traps (NETs) and thrombosis in antiphospholipid syndrome

Cited by 26 publications

References 31 publications

Anticoagulant Therapy in Patients with Antiphospholipid Syndrome

Anticoagulant Therapy in Patients with Antiphospholipid Syndrome

Research trends and frontiers on antiphospholipid syndrome: A 10-year bibliometric analysis (2012–2021)

Beta 2 glycoprotein I and neutrophil extracellular traps: Potential bridge between innate and adaptive immunity in anti-phospholipid syndrome

Contact Info

Product

Resources

About